Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Special Protocol Assessment For Navidea’s Parkinson’s Diagnostic Could Help With Coverage

This article was originally published in The Pink Sheet Daily

Executive Summary

Company expects to have data to support reimbursement of its radiopharmaceutical diagnostic NAV5001 and avoid the Medicare coverage struggles encountered by Lilly’s Amyvid; SPA reached with FDA encompasses two Phase III trials with 550 total patients.

Advertisement

Related Content

Lilly Says CMS Review Of Beta-Amyloid PET Goes Beyond Medicare Statutory Criteria

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS076152

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel